The PPARs-agonists (GW409544 and rosiglitazone) reduced hyperlipidemia via boosting malonyl-CoA decarboxylase protein production (MCD), which reduces the risk of myocardial infarction in patients with metabolic syndrome [23]. Here, MLYCD is linked to hyperlipidemia.